Equities Analysts Set Expectations for Dynavax Technologies Co.'s FY2026 Earnings (NASDAQ:DVAX)

Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - Equities researchers at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for shares of Dynavax Technologies in a report released on Monday, October 14th. HC Wainwright analyst E. White now expects that the biopharmaceutical company will earn $0.32 per share for the year, down from their prior estimate of $0.33. HC Wainwright has a "Buy" rating and a $29.00 price target on the stock. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.16 per share.

Separately, The Goldman Sachs Group cut their price objective on Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating for the company in a report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Dynavax Technologies presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.67.

Dynavax Technologies Stock Up 2.5 %

Shares of NASDAQ DVAX traded up $0.27 during trading hours on Wednesday, hitting $11.03. The company had a trading volume of 1,642,740 shares, compared to its average volume of 2,055,641. The stock has a market capitalization of $1.44 billion, a P/E ratio of 183.83 and a beta of 1.37. The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $15.15. The firm's 50 day moving average is $11.05 and its 200-day moving average is $11.29.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The company had revenue of $73.80 million during the quarter, compared to analysts' expectations of $76.92 million. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. During the same period last year, the business earned $0.03 EPS.

Institutional Investors Weigh In On Dynavax Technologies

Hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 1,685 shares during the last quarter. Algert Global LLC acquired a new stake in Dynavax Technologies during the 2nd quarter valued at $140,000. Sanctuary Advisors LLC acquired a new stake in Dynavax Technologies during the 2nd quarter valued at $182,000. XTX Topco Ltd bought a new position in Dynavax Technologies during the 2nd quarter worth $184,000. Finally, Duality Advisers LP bought a new position in Dynavax Technologies during the 1st quarter worth $227,000. Institutional investors and hedge funds own 96.96% of the company's stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.